Dx Deals: Quest Closes PathAI Partial Acquisition and Strategic Alliance
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.
Most diagnostics companies experienced modest, flat, or negative top-line revenue growth rates in the first quarter of 2022.
In this month’s Business Roundup, we cover key happenings including Medicare coverage and reimbursement, as well as the US surpassing Europe as medtech’s market of choice.
Healthcare M&A might have bottomed out in the first quarter of 2022 in terms of both deal volume and size, according to a new report.
InspectIR COVID-19 device detects the virus from breath samples in less than three minutes, offering a new screening option.
The recently-formed Precision Cancer Consortium will make it easier for cancer patients around the world to get access to genomic testing.
The HHS recently published previously confidential data relating to consolidation of hospitals and nursing homes enrolled in Medicare.
The FDA has plans to ensure COVID-19 test makers won’t be left high and dry when the public health emergency ends.
A hot trend in capital raising for the healthcare and life sciences industries only two years ago, SPAC deals have petered out, but are far from dead.
According to a recent report, this market will see almost seven percent annual growth over the next five years, reaching US $1.29 billion in 2026.
The House Energy and Commerce Committee is considering a pair of rival bills, one Democratic and one Republican, to reform the AA process.